Why Aurobindo Pharma-Sandoz deal fell apart? Check brokers' reactions
Hyderabad-based Aurobindo Pharma's decision to break its deal with Sandoz will likely impact the company and its stocks according to analysts who track the sector. The biggest reason why this decision has been taken is due to the company not getting approval from US Federal Trade Commission (FTC)
Indian pharmaceutical major was expecting the deal to happen by March 2020, the company had indicated in its guidance